Selvipharma SRL
2.5 FTESelvipharma reported total assets of 109,734 € at the end of the 2024 financial year (annual accounts filed with the NBB on 27 Nov 2025), with 2.5 full-time equivalents.
The score of Selvipharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2024
Change 2021 → 2024: Equity +150 % Total assets +18 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Selvipharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2024filed on 27 Nov 2025
- Year ended 31 Dec 2023filed on 30 Aug 2024
- Year ended 31 Dec 2022filed on 29 Sep 2023
- Year ended 31 Dec 2021filed on 05 Aug 2022
- Year ended 31 Dec 2020filed on 13 Oct 2021
Selvipharma's financial analysis
- Solvency38.8%sector median: 37.8%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Selvipharma
Selvipharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0635.925.961
- VAT number
- BE0635925961
- Peppol
- Registered · 0208:0635925961 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 01 Sep 2015
- Registered office
- 1000 Brussels
- Size
- Micro · 2.5 FTE
- Latest accounts
- 2024 · filed on 27 Nov 2025
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Selvipharma (SRL) has been based in Brussels since 2015, active in: retail sale of pharmaceutical products. For 2024, it reports a net profit of 6,068 € and equity of 42,606 €; its revenue is not published. With 2.5 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 38.8%, above the median of its sector (37.8%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Selvipharma
Companies in the same business, of comparable size and area, outside its group.
- Apotheek Verse Retail sale of pharmaceutical products Brussels · balance sheet 98,336 €
- Grodt Retail sale of pharmaceutical products Uccle · balance sheet 109,794 €
- Pharmanou Retail sale of pharmaceutical products Sprimont · balance sheet 112,116 €
- Pharmacie LEFEBVRE Retail sale of pharmaceutical products Leuven · balance sheet 112,505 €
- PPPharmacy Retail sale of pharmaceutical products Ghent · balance sheet 106,768 €
- Merckx Retail sale of pharmaceutical products Wichelen · balance sheet 106,701 €
- Parapharmacie Discount Braine l'Alleud Retail sale of pharmaceutical products Braine-l'Alleud · balance sheet 113,264 €
- SAB Pharma Retail sale of pharmaceutical products Péruwelz · balance sheet 106,135 €
Frequently asked questions about Selvipharma
What is the revenue of Selvipharma?
Selvipharma files its accounts in a format where revenue is optional: it is not published for 2024.
What is the VAT number of Selvipharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0635925961 for Selvipharma, if the company is VAT-registered. Its company number (CBE) is 0635.925.961.
Where is the registered office of Selvipharma?
According to the CBE register, the registered office of Selvipharma is in 1000 Brussels.
What is the equity of Selvipharma?
At the close of the 2024 financial year, the equity of Selvipharma amounts to 42,606 €, a solvency of 38.8% of total assets.
How many people work at Selvipharma?
2.5 full-time equivalents on average according to the 2024 social balance sheet.
Who manages Selvipharma?
The register lists 2 active mandates at Selvipharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Selvipharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →